Please login to the form below

Not currently logged in
Email:
Password:

Empliciti

This page shows the latest Empliciti news and features for those working in and with pharma, biotech and healthcare.

AbbVie's PARP inhibitor veliparib fails to deliver

AbbVie's PARP inhibitor veliparib fails to deliver

AbbVie will draw comfort from its stake in three fast-growing blood cancer drugs - Imbruvica (ibrutinib), Venclexta (venetoclax) and Empliciti (elotuzumab) - and several mid-stage candidates including antibody drug conjugates (ADCs)

Latest news

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

  • J&J gets CHMP backing for broader Darzalex use J&J gets CHMP backing for broader Darzalex use

    Takeda's orally-active proteasome inhibitor Ninlaro (ixazomib), Novartis' HDAC inhibitor Farydak (panobinostat) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) are all jostling for market share with Darzalex at

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Meanwhile other new myeloma drugs - including Johnson &Johnson's anti-CD38 antibody Darzalex (daratumumab) and Bristol-Myers Squibb's SLAMF7 inhibitor Empliciti (elotuzumab) - are also expected to compete strongly with Kyprolis

  • J&J gets European OK for myeloma therapy Darzalex J&J gets European OK for myeloma therapy Darzalex

    Farydak (panobinostat) and SLAMF7 inhibitor Bristol-Myers Squibb's Empliciti (elotuzumab). ... The market research firm predicts Empliciti could reach peak sales of $4.2bn, ahead of Darzalex with sales of $3.7bn in that year.

  • BMS gets two new cancer approvals in Europe BMS gets two new cancer approvals in Europe

    BMS gets two new cancer approvals in Europe. Empliciti, and Opdivo and Yervoy inhibitor combination get the green light. ... Empliciti has been tipped as a potential $4bn-plus product at peak by analysts at GlobaData, despite increasing competition in

More from news
Approximately 6 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics